Auvelity is NOT approved or indicated for treating anxiety disorders
Auvelity (dextromethorphan-bupropion) is FDA-approved exclusively for major depressive disorder (MDD) in adults and should not be used to treat anxiety as a primary condition 1. The FDA labeling explicitly states that "Auvelity is not approved for uses other than the treatment of MDD" 1.
Key Evidence Against Use for Anxiety
FDA Labeling is Clear
The drug label provides no indication for anxiety disorders. In fact, anxiety is listed as a common adverse effect occurring in 4% of patients treated with Auvelity versus 1% with placebo, and anxiety was the most common reason for treatment discontinuation (2% of patients) 1, 2.
Bupropion Component Can Worsen Anxiety
The bupropion component of Auvelity has well-documented anxiogenic potential, particularly at higher doses 3, 4. While some evidence suggests bupropion may reduce anxiety symptoms in depressed patients with mild-to-moderate comorbid anxiety, it can provoke or worsen anxiety due to its stimulating noradrenergic and dopaminergic properties 4.
Guideline-Recommended Treatments for Anxiety
Current clinical practice guidelines for anxiety disorders recommend:
- First-line: SSRIs (escitalopram, sertraline, paroxetine, fluvoxamine) and SNRIs (venlafaxine, duloxetine) 5, 6
- Not mentioned: Bupropion or dextromethorphan-bupropion combinations are absent from anxiety disorder treatment algorithms 5, 6
Clinical Context: MDD with Comorbid Anxiety
If the question pertains to treating depression in patients who also have anxiety symptoms, the evidence is more nuanced:
- Auvelity demonstrated efficacy in treating MDD in clinical trials, with remission rates of 46.5% versus 16.2% for bupropion alone 7, 8
- However, anxiety symptoms were not a primary outcome in these trials 7
- Post-hoc analyses suggest bupropion may help comorbid anxiety in depression, but SSRIs show modest superiority in patients with high baseline anxiety 3
Safety Concerns Specific to Anxiety
The FDA labeling warns about several neuropsychiatric effects that could worsen anxiety:
- Activation/agitation as a black box warning concern 1
- Manic episodes with symptoms including "severe trouble sleeping, racing thoughts, excessive happiness or irritability" 1
- Psychosis and unusual thoughts or behaviors 1
Bottom Line Algorithm
For primary anxiety disorders: Do not use Auvelity. Choose SSRIs (escitalopram, sertraline) or SNRIs (venlafaxine, duloxetine) as first-line 5, 6.
For MDD with mild-moderate comorbid anxiety: Auvelity may be considered if depression is the primary target, but monitor closely for anxiety worsening. Start at the lower dose (once daily for 3 days) before escalating 1.
For MDD with severe anxiety or anxious distress: Prefer SSRIs or SNRIs over Auvelity, as they have established efficacy for both conditions 6, 3.
Critical Pitfall to Avoid
Do not prescribe Auvelity off-label for anxiety disorders based on the presence of bupropion, which has mixed anxiolytic/anxiogenic effects. The combination's primary mechanism (NMDA antagonism via dextromethorphan) has not been studied for anxiety as a primary indication, and the drug carries a 4% risk of treatment-emergent anxiety 1, 2.